Biohaven Pharmaceutical Holding Company Ltd.
BHVN
BHVN was delisted on the 3rd of October, 2022.
1 hedge funds and large institutions have $19.7M invested in Biohaven Pharmaceutical Holding Company Ltd. in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less capital invested
Capital invested by funds: $27M → $19.7M (-$7.26M)
50% less funds holding
Funds holding: 2 → 1 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Birchview Capital
Burlington,
Vermont
|
-$670K |
BHVN Hedge Fund Activity: Q1 2026 in Review
1 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q1 2026, worth a combined $19.7M — down 27% from $27M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BHVN and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Birchview Capital, exiting entirely with an estimated $670K sold.
- 1 institutional investor held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q1 2026, down from 2 in Q4 2025.
- Funds reported $19.7M of Biohaven Pharmaceutical Holding Company Ltd. stock for Q1 2026, down 27% quarter-over-quarter.
- 0 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q1 2026 and 1 closed out, a net change of -1 holder.
- The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q1 2026 was Birchview Capital, an estimated $670K sold.
Based on aggregated 13F filings for Q1 2026.